Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world experience with IDH inhibitors in Acute Myeloid Leukemia: A german multicenter analysis with a focus on differentiation syndrome

View Full Paper
Ask AI
Bookmark
Share

Authors

TLTim LohmannHDHartmut DöhnerTSTim Sauer

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals IDH inhibitors improve outcomes in AML patients, highlighting differentiation syndrome risks.

Key Points

  • To evaluate the clinical activity of IDH inhibitors in acute myeloid leukemia with a focus on differentiation syndrome.
  • Retrospective analysis conducted across eleven German tertiary care centers.
  • Data collected from medical chart reviews of AML patients receiving IDH inhibitors outside clinical trials.
  • Responses evaluated based on ELN 2022 criteria and co-mutations analyzed.
  • Fifty-six AML patients included; most had IDH1 mutations and were treated with ivosidenib.
  • Clinically relevant differentiation syndrome occurred in 29% of patients; onset varied widely.
  • Significant rate of febrile neutropenia observed in 52% of patients.

Cite This Study

Lohmann et al. (2025) studied this question.

synapsesocial.com/papers/693624ce4fa91c937236cf8fhttps://doi.org/10.1182/blood-2025-2846
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Ivosidenib leads to durable responses in IDH1 mutated clonal cytopenias of undetermined significance: A phase II decentralized clinical trial2025 · 2 citations
  2. 2Differentiation syndrome associated with treatment with <i>IDH2</i> inhibitor enasidenib: pooled analysis from clinical trials2024 · 12 citations
  3. 3Retrospective study of ivosidenib for patients with recurrent IDH mutant gliomas.2024 · 2 citations
  4. 4Long-term (74-month) efficacy and safety of ivosidenib and azacitidine in an elderly patient with mutated <i>IDH1</i> acute myeloid leukemia: insights from a case report2026 · 1 citations
  5. 5Data from Multi-center phase I trial of Ivosidenib as Maintenance Treatment following Allogeneic Hematopoietic Cell Transplantation for &lt;i&gt;IDH1&lt;/i&gt;-Mutated Acute Myeloid Leukemia2024